Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25728203 | 1.00 | NPSR1 (0.37) | NPSR1ALDH1A1MAPTPKMHPGD | |
| SCHEMBL21459867 | 0.88 | KDM4E (0.41) | NPSR1ALDH1A1MAPTHPGDTP53 | |
| SCHEMBL24257302 | 0.85 | ALDH1A1 (0.38) | NPSR1ALDH1A1MAPTPKMHPGD | |
| SCHEMBL24929758 | 0.84 | ELANE (0.38) | ALDH1A1MAPTHSD17B10TP53 | |
| SCHEMBL38659645 | 0.81 | POLB (0.37) | NPSR1ALDH1A1MAPTHPGDNPC1 | |
| SCHEMBL25656378 | 0.78 | OPRK1 (0.43) | NPSR1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL25728204 | 0.78 | OPRK1 (0.43) | NPSR1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL11876232 | 0.77 | TRIM24 (0.37) | ALDH1A1MCL1 | |
| SCHEMBL24929755 | 0.76 | ALDH1A1 (0.34) | NPSR1ALDH1A1MAPT | |
| SCHEMBL25118202 | 0.76 | ELANE (0.49) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | NPSR1 2527/4885ALDH1A1 1636/4885MAPT 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.